The company plans to utilize the net proceeds, combined with its existing resources, for various purposes including research, clinical and process development, manufacturing, working capital, commercialization infrastructure and potential acquisitions or investments. BofA Securities is serving as the sole book-running manager for the offering.

See Also: What’s Going On With Rivian Automotive Stock Today?

Is STRO A Good Stock To Buy?

Wall Street analysts view Sutro Biopharma on the whole as a Outperform, given the history of coverage over the past three months. David Nierengarten from Wedbush in Sutro Biopharma is the most bearish, expecting a 33.33% fall in the stock in the coming year.

But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, Sutro Biopharma rose 14.01%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 1217.44% over the past year.

A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.

STRO has a 52-week high of $6.13 and a 52-week low of $2.00.